INVESTMENT-MARRAKECH
7.4.2022 11:30:07 CEST | Business Wire | Press release
In collaboration with the International Finance Corporation (IFC) and the Swiss State Secretariat for Economic Affairs (SECO), the Marrakech-Safi Regional Center for Investment hosted the inaugural edition of the Marrakech Investor Day , a meaningful event designed to allow hundreds of investors to explore the fantastic advantages and new investment opportunities across Marrakech.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220407005464/en/
Global supply chain disruptions, recent geopolitical changes, and the “Green Production” requirement, coupled with the multiple free trade agreements that provide direct access to more than 1.3 billion consumers, have aptly positioned Marrakech as the sustainable alternative for investors around the world.
Marrakech is a captivating imperial city boasting a sub-tropical mild climate and beautiful landscapes that make it an unmissable tourist destination. Moreover, Morocco provides attractive advantages for investors from all over the world. These advantages include political stability, a geo-strategic location and direct access to Europe and Africa’s markets, an attractive business-friendly environment, a robust, modern infrastructure, and prestigious talents taught in two of Africa’s best universities, all combined with a unique lifestyle and improved quality of life.
Marrakech, a city at the forefront of sustainability
Driven by the unrelenting will of the King of Morocco, with a target to generate 52% of energy from renewable sources by 2030, Marrakech offers investors the opportunity to put a little “green” in their portfolios and decarbonize the world’s industries.
The event was also an opportunity to explore the cultural richness and diversity of Marrakech, which actively encourages and facilitates foreign investments in multiple sectors, such as the agribusiness, tourism, creative industries, renewable energy, logistics, offshoring, and ICT.
These investment opportunities were made possible thanks to multiple reforms and facilitation mechanisms, which offer several incentives to stimulate investment (up to 30% of the total investment amount), improve the business climate and the competitiveness of the private sector.
More than 50 non-double taxation agreements, the absence of restrictions in the percentage of share capital and the free repatriation of funds are also influential factors that enable the region to offer a particularly modern and attractive legal and fiscal environment.
As part of the Marrakech Investor Day’s events, international investors were given a first-hand demonstration of these advantages that promote ease of doing investments in Marrakech and enhance transparency, such as the dematerialization of customs procedures and the personalized support of the Marrakech-Safi Regional Center for Investment.
The event also featured a panel discussion on the data-related investment opportunities, followed by the Marrakech Investor Awards ceremony, designed to celebrate the regions’ key investors.
To relive the event, and learn more about investment opportunities in Marrakech, visit www.marrakechinvest.ma
About:
The Regional Investment Center of Marrakech-Safi is a public institution with a mission is to facilitate, support and promote investments in the Marrakech-Safi region.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20220407005464/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datavault AI Announces Board of Directors Has Requested Management’s Complete Plan for Dividend Spin-Out of Acoustic Sciences Division into Stand-Alone Public Company7.5.2026 15:07:00 CEST | Press release
Initial planning calls for Data Sciences Division to focus efforts in cyber secure infrastructure with dedication in fintech and patented Information Data Exchange® (IDE®) Management will harness its API Media acquisition, robust patent portfolio, ADIO® Inaudible Tones, WiSA® and Dolby® partnerships to establish worldwide acoustic industry standards in high-definition wireless transmission, spatial-audio control and interoperability Plan includes API media’s stand-alone and renewed execution of WiSA semiconductor and software modules strategy with an R&D effort targeted to new robotic and drone applications Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a pioneering technology licensing company seeking to redefine data valuation, monetization, and secure Web 3.0 experiences, today announced that Company management has commenced its evaluation of a potential dividend spin-out of the Company’s Acoustic Sciences division which includes its ADIO®, WiSA®, Event Citadel™,
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 14:50:00 CEST | Press release
First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs)at the 2026 EADV SymposiumThe vast majority of patients achieving EASI50 at Week 8 and continuing double-blind, as needed treatment with Opzelura® (ruxolitinib) cream through Week 24 demonstrated disease control, with 84.3% achieving EASI75 (a ≥75% improvement in the Eczema Area and Severity Index score from baseline) and 70.6% achieving IGA-TS (Investigator’s Global Assessment Treatment Success)Data support Type-II variation application submitted for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU), feedback expected in 1H 2026 Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with mode
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release
Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release
“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
